MARC HOROWITZ to Brain Neoplasms
This is a "connection" page, showing publications MARC HOROWITZ has written about Brain Neoplasms.
Connection Strength
0.387
-
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
Score: 0.074
-
A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer. 1995 Jun 01; 75(11):2762-7.
Score: 0.038
-
Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol. 2014 Mar; 16(3):457-65.
Score: 0.034
-
Feasibility and efficacy of preirradiation chemotherapy for pediatric brain tumors. Neurosurgery. 1988 Apr; 22(4):687-90.
Score: 0.023
-
Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer. 1988 Feb 01; 61(3):428-34.
Score: 0.023
-
Development and characterization of human ependymoma xenograft HxBr5. Cancer Res. 1987 Jan 15; 47(2):499-504.
Score: 0.021
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
Score: 0.020
-
Regional [14C]misonidazole distribution in experimental RT-9 brain tumors. Cancer Res. 1983 Aug; 43(8):3800-7.
Score: 0.017
-
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999 04; 1(2):152-61.
Score: 0.012
-
Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998 Sep; 44(3):313-6.
Score: 0.012
-
Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg. 1998 Apr; 28(4):215-22.
Score: 0.012
-
Primary malignant rhabdoid tumor of the central nervous system. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):361-8.
Score: 0.011
-
Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):369-78.
Score: 0.011
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.010
-
Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol. 1996 May-Jun; 28(2-3):245-56.
Score: 0.010
-
Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. Med Pediatr Oncol. 1995 Jul; 25(1):38-44.
Score: 0.010
-
Desmoplastic infantile gangliogliomas: an approach to therapy. Neurosurgery. 1994 Apr; 34(4):583-9; discussion 589.
Score: 0.009
-
A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer. 1993 Jul 01; 72(1):271-5.
Score: 0.008
-
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993 Jun 17; 328(24):1725-31.
Score: 0.008
-
Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg. 1993 May-Jun; 19(3):113-8; discussion 119-20.
Score: 0.008
-
Regional blood flow in ethylnitrosourea-induced brain tumors. Ann Neurol. 1983 Aug; 14(2):189-201.
Score: 0.004
-
Regional blood-to-tissue transport in ethylnitrosourea-induced brain tumors. Ann Neurol. 1983 Aug; 14(2):202-15.
Score: 0.004
-
Regional blood-to-tissue transport in RT-9 brain tumors. J Neurosurg. 1983 Jun; 58(6):874-84.
Score: 0.004
-
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19; 332(3):143-9.
Score: 0.002